1. Ali H, Mohamed MM, Sharma A, Fulop T, Halawa A. Outcomes of interleukin-2 receptor antagonist induction therapy in standard-risk renal transplant recipients maintained on tacrolimus: a systematic review and meta-analysis. Am J Nephrol. 2021;52(4):279–91.
2. Ali H, Sharma A, Halawa A. Effect of interleukin-2 receptor antibody induction therapy on survival in renal transplant patients receiving tacrolimus. Am J Nephrol. 2020;51(5):366–72.
3. Ali H, Mohiuddin A, Sharma A, Shaheen I, Kim JJ, El Kosi M, et al. Implication of interleukin-2 receptor antibody induction therapy in standard risk renal transplant in the tacrolimus era: a meta-analysis. Clin Kidney J. 2019;12(4):592–9.
4. Opelz G, Collaborative Transplant S. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet. 2005 Apr 30–May 6;365(9470):1570–6.
5. Gebel HM, Bray RA, Ruth JA, Zibari GB, McDonald JC, Kahan BD, et al. Flow PRA to detect clinically relevant HLA antibodies. Transplant Proc. 2001 Feb–Mar;33(1–2):477.